Table 1.
Basic characteristics in patients with idiopathic pulmonary artery hypertension.
| Variables | Normouricemia | Hyperuricemia | All | P-value |
|---|---|---|---|---|
| (n = 86) | (n = 121) | (n = 207) | ||
| Age, years | 33.4 ± 11.5 | 31.5 ± 9.6 | 32.3 ± 10.5 | 0.196 |
| Female, n (%) | 72 (83.7) | 85 (70.2) | 157 (75.8) | 0.018 |
| BMI, kg/m2 | 21.9 ± 3.4 | 23.0 ± 3.5 | 22.5 ± 3.5 | 0.025 |
| WHO FC, I/II/III/IV, n | 6/43/35/2 | 1/60/55/5 | 7/103/90/7 | 0.095 |
| Deaths, n (%) | 6 (7.0) | 26 (21.5) | 32 (15.5) | 0.003 |
| Hemodynamic indices | ||||
| RAP, mmHg | 4.0 ± 3.6 | 6.1 ± 4.7 | 5.2 ± 4.4 | <0.001 |
| mPAP, mmHg | 54.9 ± 15.5 | 60.9 ± 16.5 | 58.4 ± 16.3 | 0.009 |
| PVR, Wood units | 10.4 ± 5.1 | 14.3 ± 6.6 | 12.7 ± 6.3 | <0.001 |
| CI, ml/min/m2 | 3.2 ± 1.0 | 2.5 ± 0.7 | 2.8 ± 0.9 | <0.001 |
| Laboratory tests | ||||
| WBC, × 109/L | 6.5 ± 1.7 | 7.5 ± 3.1 | 7.1 ± 2.6 | 0.005 |
| Neutrophils, % | 57.5 ± 9.9 | 56.4 ± 10.8 | 56.8 ± 10.4 | 0.472 |
| Platelet, × 109/L | 191.4 ± 52.8 | 184.6 ± 62.2 | 187.4 ± 58.4 | 0.414 |
| Albumin, g/L | 41.9 ± 5.1 | 42.0 ± 4.5 | 42.0 ± 4.7 | 0.854 |
| TBIL, μmol/L | 18.1 ± 9.2 | 23.4 ± 12.5 | 21.2 ± 11.6 | 0.001 |
| DBIL, μmol/L | 3.6 ± 2.2 | 5.3 ± 4.6 | 4.6 ± 3.8 | 0.001 |
| Creatinine, μmol/L | 62.1 ± 12.0 | 75.6 ± 23.0 | 70.0 ± 20.3 | <0.001 |
| BUN, mmol/L | 4.7 ± 1.7 | 6.1 ± 2.3 | 5.5 ± 2.2 | <0.001 |
| eGFR, ml/min/m2 | 124.3 ± 28.2 | 93.4 ± 17.7 | 109.3 ± 23.2 | <0.001 |
| ESR, mm/h | 3.0 (2.0–7.0) | 2.0 (1.0–6.0) | 2.0 (2.0–6.5) | 0.527 |
| CRP, mg/L | 2.0 (1.5–3.4) | 2.8 (1.9–4.2) | 2.5 (1.7–3.8) | 0.698 |
| Cholesterol, mmol/L | 4.0 ± 0.8 | 4.0 ± 0.9 | 4.0 ± 0.9 | 0.745 |
| LDH, U/L | 188 (161–219) | 225 (192–270) | 210 (180–255) | 0.177 |
| NT-proBNP, pg/mL | 1,009.4 ± 790.9 | 1,510.0 ± 1,022.3 | 1,302.0 ± 963.3 | <0.001 |
| Uric acid, μmol/L | 301.7 ± 51.6 | 503.8 ± 108.4 | 418.6 ± 129.6 | <0.001 |
| Digoxin, n (%) | 74 (86.0) | 108 (89.3) | 182 (87.9) | 0.485 |
| Diuretics, n (%) | 86 (100.0) | 120 (99.2) | 206 (99.5) | 0.398 |
| Warfarin, n (%) | 71 (82.6) | 97 (80.2) | 168 (81.2) | 0.664 |
| Targeted Therapy†, n (%) | 72 (83.7) | 105 (86.8) | 177 (85.5) | 0.538 |
| Monotherapy, n (%) | 69 (80.2) | 102 (84.3) | 171 (82.6) | 0.447 |
| ERAs, n (%) | 12 (14) | 17 (14) | 29 (14) | 0.984 |
| PDE-5 is, n (%) | 55 (64.0) | 77 (63.6) | 132 (63.8) | 0.963 |
| Prostanoids, n (%) | 2 (2.3) | 8 (6.6) | 10 (4.8) | 0.156 |
| Combined therapy, n (%) | 3 (3.5) | 3 (2.5) | 6 (2.9) | 0.670 |
| ERAs + PDE-5 is, n (%) | 3 (3.5) | 3 (2.5) | 6 (2.9) | 0.670 |
Values are expressed mean ± standard deviation or mean (interquartile range) or n%. BMI, body mass index; WHO FC, World Health Organization functional classes; RAP, right atrial pressure; mPAP, mean pulmonary artery pressure; PVR, pulmonary vascular resistance; CI, cardiac index; WBC, white blood cells; TBIL, total bilirubin; DBIL, direct bilirubin; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; ESR, erythrocyte sedimentation rate; CRP, C-reactive peptide; LDH, lactate dehydrogenase; NT-proBNP, N-terminal pro-B type natriuretic peptide; ERAs, endothelin receptor antagonists; PDE-5 is phosphodiesterase-5 inhibitors.
At index hospitalization.